Form 4: Decheng Capital Funds Sell BYSI Shares

Decheng Capital-affiliated funds, including a 10% owner and director, reported sales of BeyondSpring Inc. ordinary shares totaling 4,900 shares.

Summary

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director of BeyondSpring Inc. (BYSI), sold 4,900 ordinary shares.
• On August 14, 2025, 2,000 shares were sold at a weighted average price of $2.00 per share, with prices ranging from $2.00 to $2.01.
• On August 15, 2025, an additional 2,900 shares were sold at a weighted average price of $2.00 per share, with prices ranging from $2.00 to $2.01.
• Following these transactions, Decheng Capital China Life Sciences USD Fund III, L.P. beneficially owns 1,974,172 ordinary shares.
• Other affiliated funds, Decheng Capital China Life Sciences USD Fund II, L.P. and Decheng Capital Global Healthcare Fund (Master), LP, continue to hold 1,617,409 and 891,734 ordinary shares, respectively.
• Dr. Xiangmin Cui, manager of the general partners for these funds, is also a reporting person and disclaims beneficial ownership except for his proportionate pecuniary interest.

Sentiment

Score: 3

Explanation: The sentiment is negative due to insider selling by a significant institutional investor and director. While the volume is small, it signals a reduction in conviction or a portfolio rebalancing, which can be perceived negatively by the market.

Negatives

• A significant shareholder and director, Decheng Capital, has reduced its holdings in BeyondSpring Inc.
• Insider selling can be interpreted by the market as a lack of confidence in the company's near-term prospects or valuation.

Risks

• Potential negative market reaction due to insider selling, which could lead to downward pressure on BeyondSpring Inc.'s stock price.
• Reduced alignment of interests between a major institutional investor/director and common shareholders as their stake decreases.

Future Outlook

NA

Industry Context

This insider selling event occurs within the biotechnology and pharmaceutical industry, where investor sentiment can be highly sensitive to clinical trial results, regulatory approvals, and funding news. While the sale amount is relatively small, any reduction in holdings by a significant institutional investor and director can be scrutinized for underlying reasons, especially in a sector often reliant on long-term capital commitment.

Related Party Transactions

• Decheng Capital China Life Sciences USD Fund III, L.P., a 10% owner and director, sold shares of BeyondSpring Inc.
• Dr. Xiangmin Cui, who manages the general partners of the Decheng Capital funds, is also a reporting person associated with these transactions.

Stakeholder Impact

• Shareholders: May interpret the insider selling as a negative signal, potentially leading to decreased investor confidence and downward pressure on the stock price.

Key Dates

Recommendation

While the insider selling by Decheng Capital, a 10% owner and director, is a negative signal, the volume of shares sold (4,900) is relatively small compared to their overall holdings. This suggests it might be a portfolio rebalancing rather than a complete loss of confidence. Investors should monitor future insider activity and company developments, but a 'hold' recommendation is appropriate given the limited scale of the transaction and the need for further context.

Keywords

BeyondSpring Inc., BYSI, Decheng Capital, Insider Selling, Form 4, Share Sale, Biotechnology, Pharmaceuticals, Institutional Investor